MTOR and acute myeloid leukemia: In addition, our results also support the clinical investigation of hypomethylating agents in combination with newer generation dual mTORC1/mTORC2 inhibitors [44, 45] or compound PI3K/mTOR inhibitors [46, 47] in patients with AML.